Tenaya Therapeutics (TNYA) Total Current Liabilities (2020 - 2026)

Tenaya Therapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $16.8 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 18.58% year-over-year to $16.8 million in Q1 2026; TTM through Mar 2026 was $16.8 million, a 18.58% increase from a year earlier, with the FY2025 full-year figure at $15.4 million, down 3.37% from the prior year.
• Total Current Liabilities improved to $16.8 million in Q1 2026 per TNYA's latest filing, from $15.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $24.2 million in Q4 2022 and bottomed at $12.7 million in Q2 2025.
• The 5-year median for Total Current Liabilities is $17.7 million (2022), against an average of $17.8 million.
• Across the five-year window, Total Current Liabilities soared 91.23% in 2022 and slipped 29.73% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $24.2 million in 2022, then retreated by 6.25% to $22.7 million in 2023, then declined by 29.73% to $16.0 million in 2024, then slipped by 3.37% to $15.4 million in 2025, then climbed by 8.71% to $16.8 million in 2026.
• Per Business Quant, the three latest TNYA Total Current Liabilities figures stand at $16.8 million (Q1 2026), $15.4 million (Q4 2025), and $13.2 million (Q3 2025).